Cyclin-dependent kinase 11 (CDK11) is crucial in the growth of liposarcoma cells

Cancer Letters

Volumn 342, Issue 1, 2014, Pages 104-112

  Jia, Bin ^a,b   Choy, Edwin ^a   Cote, Gregory ^a   Harmon, David ^a   Ye, Shunan ^a   Kan, Quancheng ^b   Mankin, Henry ^a   Hornicek, Francis ^a   Duan, Zhenfeng ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

Author keywords

CDK11; Immunohistochemistry; Kinase; Liposarcoma; Tissue microarray

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 11; DOXORUBICIN; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; SURVIVIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CELL GROWTH; CELL NUCLEUS; CELL PROLIFERATION; CELL SURVIVAL; CELLULAR DISTRIBUTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFICACY; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIPOSARCOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TARGETING; TISSUE MICROARRAY;

CDK11; IMMUNOHISTOCHEMISTRY; KINASE; LIPOSARCOMA; TISSUE MICROARRAY;

ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYCLIN-DEPENDENT KINASES; DOXORUBICIN; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; LIPOMA; LIPOSARCOMA; MALE; MIDDLE AGED; RNA, SMALL INTERFERING; TISSUE ARRAY ANALYSIS;

EID: 84887609342     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.08.040     Document Type: Article

References (43)

1. Matushansky I., Hernando E., Socci N.D., Matos T., Mills J., Edgar M.A., Schwartz G.K., Singer S., Cordon-Cardo C., Maki R.G. A developmental model of sarcomagenesis defines a differentiation-based classification for liposarcomas. The American Journal of Pathology 2008, 172:1069-1080.
2. Murphey M.D. World health organization classification of bone and soft tissue tumors: modifications and implications for radiologists. Seminars in Musculoskeletal Radiology 2007, 11:201-214.
3. Sleijfer S., Ouali M., van Glabbeke M., Krarup-Hansen A., Rodenhuis S., Le Cesne A., Hogendoorn P.C., Verweij J., Blay J.Y. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG). European Journal of Cancer 2010, 46:72-83.
4. Van Glabbeke M., van Oosterom A.T., Oosterhuis J.W., Mouridsen H., Crowther D., Somers R., Verweij J., Santoro A., Buesa J., Tursz T. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens-a European organization for research and treatment of cancer soft tissue and bone sarcoma group study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 1999, 17:150-157.
5. Ghadimi M.P., Al-Zaid T., Madewell J., Peng T., Colombo C., Hoffman A., Creighton C.J., Zhang Y., Zhang A., Lazar A.J., Pollock R.E., Lev D. Diagnosis, management, and outcome of patients with dedifferentiated liposarcoma systemic metastasis. Annals of Surgical Oncology 2011, 18:3762-3770.
6. Lopes L.F., Bacchi C.E. Imatinib treatment for gastrointestinal stromal tumour (GIST). Journal of Cellular and Molecular Medicine 2010, 14:42-50.
7. Demicco E.G., Torres K.E., Ghadimi M.P., Colombo C., Bolshakov S., Hoffman A., Peng T., Bovee J.V., Wang W.L., Lev D., Lazar A.J. Involvement of the PI3K/Akt pathway in myxoid/round cell liposarcoma. Modern Pathology: an Official Journal of the United States and Canadian Academy of Pathology, Inc. 2012, 25:212-221.
8. Dass C.R., Galloway S.J., Clark J.C., Khachigian L.M., Choong P.F. Involvement of c-jun in human liposarcoma growth: supporting data from clinical immunohistochemistry and DNAzyme efficacy. Cancer Biology and Therapy 2008, 7:1297-1301.
9. Snyder E.L., Sandstrom D.J., Law K., Fiore C., Sicinska E., Brito J., Bailey D., Fletcher J.A., Loda M., Rodig S.J., Dal Cin P., Fletcher C.D. C-Jun amplification and overexpression are oncogenic in liposarcoma but not always sufficient to inhibit the adipocytic differentiation programme. The Journal of Pathology 2009, 218:292-300.
10. Blachly J.S., Byrd J.C. Emerging drug profile: cyclin-dependent kinase inhibitors. Leukemia and Lymphoma 2013.
11. Dickson M.A., Tap W.D., Keohan M.L., D'Angelo S.P., Gounder M.M., Antonescu C.R., Landa J., Qin L.X., Rathbone D.D., Condy M.M., Ustoyev Y., Crago A.M., Singer S., Schwartz G.K. Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2013.
12. Senderowicz A.M. Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials. Investigational New Drugs 1999, 17:313-320.
13. Ramaswamy B., Phelps M.A., Baiocchi R., Bekaii-Saab T., Ni W., Lai J.P., Wolfson A., Lustberg M.E., Wei L., Wilkins D., Campbell A., Arbogast D., Doyle A., Byrd J.C., Grever M.R., Shah M.H. A dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors. Investigational New Drugs 2012, 30:629-638.
14. Whitlock J.A., Krailo M., Reid J.M., Ruben S.L., Ames M.M., Owen W., Reaman G. S. Children's Oncology Group, Phase I clinical and pharmacokinetic study of flavopiridol in children with refractory solid tumors: a Children's Oncology Group Study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2005, 23:9179-9186.
15. Darpolor M.M., Kennealey P.T., Le H.C., Zakian K.L., Ackerstaff E., Rizwan A., Chen J.H., Sambol E.B., Schwartz G.K., Singer S., Koutcher J.A. Preclinical study of treatment response in HCT-116 cells and xenografts with (1) H-decoupled (31) P MRS. NMR in Biomedicine 2011, 24:1159-1168.
16. Li Y., Tanaka K., Li X., Okada T., Nakamura T., Takasaki M., Yamamoto S., Oda Y., Tsuneyoshi M., Iwamoto Y. Cyclin-dependent kinase inhibitor, flavopiridol, induces apoptosis and inhibits tumor growth in drug-resistant osteosarcoma and Ewing's family tumor cells. International Journal of Cancer. Journal International du Cancer 2007, 121:1212-1218.
17. Duan Z., Zhang J., Choy E., Harmon D., Liu X., Nielsen P., Mankin H., Gray N.S., Hornicek F.J. Systematic kinome shRNA screening identifies CDK11 (PITSLRE) kinase expression is critical for osteosarcoma cell growth and proliferation. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research 2012, 18:4580-4588.
18. Shi J., Feng Y., Goulet A.C., Vaillancourt R.R., Sachs N.A., Hershey J.W., Nelson M.A. The p34cdc2-related cyclin-dependent kinase 11 interacts with the p47 subunit of eukaryotic initiation factor 3 during apoptosis. The Journal of Biological Chemistry 2003, 278:5062-5071.
19. Sachs N.A., Vaillancourt R.R. Cyclin-dependent kinase 11p110 and casein kinase 2 (CK2) inhibit the interaction between tyrosine hydroxylase and 14-3-3. Journal of Neurochemistry 2004, 88:51-62.
20. Choi H.H., Choi H.K., Jung S.Y., Hyle J., Kim B.J., Yoon K., Cho E.J., Youn H.D., Lahti J.M., Qin J., Kim S.T. CHK2 kinase promotes pre-mRNA splicing via phosphorylating CDK11(p110). Oncogene 2012.
21. Liu X., Cheng C., Shao B., Wu X., Ji Y., Lu X., Shen A. The functional interaction between CDK11p58 and beta-1,4-galactosyltransferase I involved in astrocyte activation caused by lipopolysaccharide. Inflammation 2012, 35:1365-1377.
22. Petretti C., Savoian M., Montembault E., Glover D.M., Prigent C., Giet R. The PITSLRE/CDK11p58 protein kinase promotes centrosome maturation and bipolar spindle formation. EMBO Reports 2006, 7:418-424.
23. Hao Y., Kong X., Ruan Y., Gan H., Chen H., Zhang C., Ren S., Gu J. CDK11p46 and RPS8 associate with each other and suppress translation in a synergistic manner. Biochemical and Biophysical Research Communications 2011, 407:169-174.
24. Hu D., Mayeda A., Trembley J.H., Lahti J.M., Kidd V.J. CDK11 complexes promote pre-mRNA splicing. The Journal of Biological Chemistry 2003, 278:8623-8629.
25. Trembley J.H., Hu D., Hsu L.C., Yeung C.Y., Slaughter C., Lahti J.M., Kidd V.J. PITSLRE p110 protein kinases associate with transcription complexes and affect their activity. The Journal of Biological Chemistry 2002, 277:2589-2596.
26. Loyer P., Trembley J.H., Katona R., Kidd V.J., Lahti J.M. Role of CDK/cyclin complexes in transcription and RNA splicing. Cellular Signalling 2005, 17:1033-1051.
27. Xiang J., Lahti J.M., Grenet J., Easton J., Kidd V.J. Molecular cloning and expression of alternatively spliced PITSLRE protein kinase isoforms. The Journal of Biological Chemistry 1994, 269:15786-15794.
28. Yang W., Liu X., Choy E., Mankin H., Hornicek F.J., Duan Z. Targeting hedgehog-GLI-2 pathway in osteosarcoma. Journal of Orthopaedic Research: Official Publication of the Orthopaedic Research Society 2013, 31:502-509.
29. Binh M.B., Sastre-Garau X., Guillou L., de Pinieux G., Terrier P., Lagace R., Aurias A., Hostein I., Coindre J.M. MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms with genetic data. The American Journal of Surgical Pathology 2005, 29:1340-1347.
30. Aleixo P.B., Hartmann A.A., Menezes I.C., Meurer R.T., Oliveira A.M. Can MDM2 and CDK4 make the diagnosis of well differentiated/dedifferentiated liposarcoma? An immunohistochemical study on 129 soft tissue tumours. Journal of Clinical Pathology 2009, 62:1127-1135.
31. Singer S., Socci N.D., Ambrosini G., Sambol E., Decarolis P., Wu Y., O'Connor R., Maki R., Viale A., Sander C., Schwartz G.K., Antonescu C.R. Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma. Cancer Research 2007, 67:6626-6636.
32. Barretina J., Taylor B.S., Banerji S., Ramos A.H., Lagos-Quintana M., Decarolis P.L., Shah K., Socci N.D., Weir B.A., Ho A., Chiang D.Y., Reva B., Mermel C.H., Getz G., Antipin Y., Beroukhim R., Major J.E., Hatton C., Nicoletti R., Hanna M., Sharpe T., Fennell T.J., Cibulskis K., Onofrio R.C., Saito T., Shukla N., Lau C., Nelander S., Silver S.J., Sougnez C., Viale A., Winckler W., Maki R.G., Garraway L.A., Lash A., Greulich H., Root D.E., Sellers W.R., Schwartz G.K., Antonescu C.R., Lander E.S., Varmus H.E., Ladanyi M., Sander C., Meyerson M., Singer S. Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nature Genetics 2010, 42:715-721.
33. Schwartz G.K., LoRusso P.M., Dickson M.A., Randolph S.S., Shaik M.N., Wilner K.D., Courtney R., O'Dwyer P.J. Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1). British Journal of Cancer 2011, 104:1862-1868.
34. Lahti J.M., Xiang J., Heath L.S., Campana D., Kidd V.J. PITSLRE protein kinase activity is associated with apoptosis. Molecular and Cellular Biology 1995, 15:1-11.
35. Li T., Inoue A., Lahti J.M., Kidd V.J. Failure to proliferate and mitotic arrest of CDK11(p110/p58)-null mutant mice at the blastocyst stage of embryonic cell development. Molecular and Cellular Biology 2004, 24:3188-3197.
36. Mikolajczyk M., Nelson M.A. Regulation of stability of cyclin-dependent kinase CDK11p110 and a caspase-processed form, CDK11p46, by Hsp90. The Biochemical Journal 2004, 384:461-467.
37. Luke J.J., D'Adamo D.R., Dickson M.A., Keohan M.L., Carvajal R.D., Maki R.G., de Stanchina E., Musi E., Singer S., Schwartz G.K. The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: preclinical investigations and results of a phase I dose-escalation clinical trial. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research 2012, 18:2638-2647.
38. Fornier M.N., Rathkopf D., Shah M., Patil S., O'Reilly E., Tse A.N., Hudis C., Lefkowitz R., Kelsen D.P., Schwartz G.K. Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research 2007, 13:5841-5846.
39. Dickson M.A., Shah M.A., Rathkopf D., Tse A., Carvajal R.D., Wu N., Lefkowitz R.A., Gonen M., Cane L.M., Dials H.J., Schwartz G.K. A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol. Cancer Chemotherapy and Pharmacology 2010, 66:1113-1121.
40. Rathkopf D., Dickson M.A., Feldman D.R., Carvajal R.D., Shah M.A., Wu N., Lefkowitz R., Gonen M., Cane L.M., Dials H.J., Winkelmann J.L., Bosl G.J., Schwartz G.K. Phase I study of flavopiridol with oxaliplatin and fluorouracil/leucovorin in advanced solid tumors. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research 2009, 15:7405-7411.
41. Shah M.A., Kortmansky J., Motwani M., Drobnjak M., Gonen M., Yi S., Weyerbacher A., Cordon-Cardo C., Lefkowitz R., Brenner B., O'Reilly E., Saltz L., Tong W., Kelsen D.P., Schwartz G.K. A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research 2005, 11:3836-3845.
42. Drogat J., Migeot V., Mommaerts E., Mullier C., Dieu M., van Bakel H., Hermand D. Cdk11-cyclinL controls the assembly of the RNA polymerase II mediator complex. Cell Reports 2012, 2:1068-1076.
43. Loyer P., Trembley J.H., Grenet J.A., Busson A., Corlu A., Zhao W., Kocak M., Kidd V.J., Lahti J.M. Characterization of cyclin L1 and L2 interactions with CDK11 and splicing factors: influence of cyclin L isoforms on splice site selection. The Journal of Biological Chemistry 2008, 283:7721-7732.